Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Current Deferred Revenue (2016 - 2025)

Biomerica's Current Deferred Revenue history spans 13 years, with the latest figure at $30000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 64.71% year-over-year to $30000.0; the TTM value through Nov 2025 reached $30000.0, down 64.71%, while the annual FY2025 figure was $55000.0, 35.29% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $30000.0 at Biomerica, down from $54000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.2 million in Q1 2022 and bottomed at $30000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $60000.0 (2023), against an average of $380356.9.
  • The largest annual shift saw Current Deferred Revenue plummeted 97.72% in 2022 before it soared 41.67% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.2 million in 2021, then tumbled by 97.72% to $49013.0 in 2022, then rose by 22.42% to $60000.0 in 2023, then skyrocketed by 41.67% to $85000.0 in 2024, then tumbled by 64.71% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Current Deferred Revenue are $30000.0 (Q4 2025), $54000.0 (Q3 2025), and $55000.0 (Q2 2025).